




RealRate

PHARMACEUTICAL 2017

Syndax Pharmaceuticals Inc
Rank 134 of 313

Syndax



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai

The relative strengths and weaknesses of Syndax Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Syndax Pharmaceuticals Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 288% points. The greatest weakness of Syndax Pharmaceuticals Inc is the variable Research and Development, reducing the Economic Capital Ratio by 72% points.

The company's Economic Capital Ratio, given in the ranking table, is -131%, being 285% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	108,510
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	10,366
Liabilities, Non-Current	14,508
Other Assets	243
Other Compr. Net Income	28
Other Expenses	0
Other Liabilities	0
Other Net Income	-706
Property and Equipment	260
Research and Development	31,665
Revenues	1,220
Selling, General and Administrative Expense	13,321

Output Variable	Value in 1000 USD
Assets	109,013
Liabilities	24,874
Expenses	44,986
Stockholders Equity	84,139
Net Income	-44,472
Comprehensive Net Income	-44,458
Economic Capital Ratio	-131%